0.501  0.009 (1.93%)		10-07 16:00
Open: 0.58 High: 0.58 Volume: 200		Pre. Close: 0.49151 Low: 0.4339 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	9.99	1-year :	15.76
Resists	First :	8.55	Second :	13.5
Pivot price	7.07
Supports	First :	0.55	Second :	0.45
MAs	MA(5) :	4.36	MA(20) :	8.43
	MA(100) :	11.39	MA(250) :	22.48
MACD	MACD :	-2	Signal :	-1.6
%K %D	K(14,3) :	32.5	D(3) :	24.5
RSI	RSI(14): 39.6
52-week	High :	49.95	Low :	0.55

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ALUR ] has closed above bottom band by 34.9%. Bollinger Bands are 25.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.96 - 5.98	5.98 - 6.01
Low:	4.34 - 4.35	4.35 - 4.37
Close:	5.46 - 5.5	5.5 - 5.54

Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurion Balloon – a novel, non-surgical, swallowable intragastric device engineered to promote significant weight loss. This program is further enhanced by the Allurion Virtual Care Suite, which provides sophisticated AI-powered remote patient monitoring, a specialized behavior modification curriculum, encrypted messaging capabilities, and virtual telehealth consultations. The firm's main operational base is located in Natick, Massachusetts.

Tue, 22 Sep 2026
ALUR 10-K Filings - ALLURION TECHNOLOGIES SEC 10-K - Stock Titan

Mon, 24 Aug 2026
ALURD 8-K Filings - ALLURION TECHNOLOGIES NEW SEC 8-K - Stock Titan

Thu, 20 Aug 2026
Enterprise value to EBIT forward of Allurion Technologies Inc. – OTC:ALUR - TradingView

Wed, 17 Jun 2026
Allurion Advances Plan to Re-List - Yahoo Finance

Tue, 02 Jun 2026
Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum - Business Wire

Fri, 15 May 2026
ALUR: Q1 2026 saw a 47% revenue decline, FDA approval, and NYSE delisting amid liquidity risks - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Medical - Devices
Shares Out	15 (M)
Shares Float	15 (M)
Held by Insiders	5.1 (%)
Held by Institutions	1.1 (%)
Shares Short	476 (K)
Shares Short P.Month	490 (K)

EPS	-3.97
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-5.2
Profit Margin	-264.8 %
Operating Margin	-126.6 %
Return on Assets (ttm)	-66.9 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-47.3 %
Gross Profit (p.s.)	0.44
Sales Per Share	0.83
EBITDA (p.s.)	-1.81
Qtrly Earnings Growth	0 %
Operating Cash Flow	-23 (M)
Levered Free Cash Flow	-13 (M)

PE Ratio	-1.39
PEG Ratio	0
Price to Book value	-1.06
Price to Sales	6.55
Price to Cash Flow	-3.64

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.